Overview

Erdafitinib in Metastatic Steroid-cell Ovarian Cancer

Status:
COMPLETED
Trial end date:
2022-08-22
Target enrollment:
Participant gender:
Summary
This is a single participant study of erdafitinib for the treatment of a patient with metastatic steroid-cell tumor of the ovary.
Phase:
NA
Details
Lead Sponsor:
University Health Network, Toronto
Treatments:
erdafitinib